US Edition
Published • loading... • Updated
EMA Review of Taletrectinib in ROS1-Positive Lung Cancer Could Be A Game Changer For Nuvation Bio (NUVB)
The European Medicines Agency accepted Eisai's application for taletrectinib, a CNS-active ROS1 inhibitor, following Phase 2 TRUST studies with a decision expected in early 2027.
- Yesterday, the European Medicines Agency validated the Marketing Authorisation Application from Eisai Co., Ltd. and Nuvation Bio Inc. for taletrectinib to treat advanced ROS1-positive non-small cell lung cancer .
- Taletrectinib is already approved for advanced ROS1-positive NSCLC in the U.S., China, and Japan, where it is marketed in China by Innovent Biologics under the brand name DOVBLERON.
- The application relies on data from two pivotal Phase 2 studies, TRUST-I and TRUST-II, which evaluated taletrectinib's safety and efficacy globally with results published in Clinical Oncology in April 2025.
- Beyond Europe, Eisai plans additional filings for taletrectinib in Canada, the U.K., and other regions within its licensed territories to expand patient access to this targeted therapy.
- The filing will undergo standard review with a decision expected in 1H 2027 regarding full approval for patients with advanced ROS1-positive NSCLC in Europe, potentially bringing the therapy to thousands needing targeted options.
Insights by Ground AI
24 Articles
24 Articles
Bennington Banner+22 Reposted by 22 other sources
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline
EMA Review of Taletrectinib in ROS1-Positive Lung Cancer Could Be A Game Changer For Nuvation Bio (NUVB)
Eisai and Nuvation Bio recently announced that the European Medicines Agency has validated their Marketing Authorisation Application for taletrectinib for advanced ROS1-positive non-small cell lung cancer, moving the therapy into a standard review process for potential use across Europe. This regulatory milestone marks a key step in Nuvation Bio’s effort to turn taletrectinib into a globally accessible, next-generation option for a narrowly defi…
Coverage Details
Total News Sources24
Leaning Left2Leaning Right3Center7Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 17%
C 58%
R 25%
Factuality
To view factuality data please Upgrade to Premium
